Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

- 20 novembre 2024 - 1 mn de lecture

This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.

En rapport Clinical Trials

20 novembre 2024 1 mn de lecture

Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?

20 novembre 2024 1 mn de lecture

Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression

20 novembre 2024 1 mn de lecture

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

20 novembre 2024 1 mn de lecture

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

20 novembre 2024 1 mn de lecture

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

20 novembre 2024 1 mn de lecture

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

En rapport Clinical Trials

Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?

Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

Dysport® Pediatric Lower Limb Spasticity Follow-on Study

Dysport® Adult Lower Limb Spasticity Follow-on Study

Dysport® Pediatric Lower Limb Spasticity Study

Dysport® Adult Lower Limb Spasticity Study

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

Dysport in the Treatment of Glabellar Lines in Chinese Subjects